About IO Biotech, Inc.
https://www.iobiotech.comIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform.
CEO
Mai-Britt Zocca
Compensation Summary
(Year 2024)
Salary $567,788
Option Awards $931,350
Incentive Plan Pay $283,894
All Other Compensation $56,779
Total Compensation $1,839,811
Industry Biotechnology
Sector Healthcare
Went public November 5, 2021
Method of going public IPO
Full time employees 80
Ratings Snapshot
Rating : C-
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Overweight 2
Neutral 1
Hold 1
Showing Top 4 of 4
Price Target
Target High $3
Target Low $3
Target Median $3
Target Consensus $3
Institutional Ownership
NOVO HOLDINGS A/S
Shares:2.51M
Value:$1.35M
IKARIAN CAPITAL, LLC
Shares:1.53M
Value:$817.88K
MILLENNIUM MANAGEMENT LLC
Shares:1.39M
Value:$746.32K
Summary
% Of Shares Owned 13.75%
Total Number Of Holders 22
Showing Top 3 of 22
Market Cap $40.36 M
52w High $2.79
52w Low $0.32
P/E -0.4
Volume 1.42M
Outstanding Shares 71.95M
About IO Biotech, Inc.
https://www.iobiotech.comIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.13M ▼ | $-8.38M ▲ | 0% | $-0.13 ▲ | $-8.93M ▲ |
| Q2-2025 | $0 | $22.94M ▲ | $-26.22M ▼ | 0% | $-0.4 ▼ | $-25.61M ▼ |
| Q1-2025 | $0 | $22.36M ▼ | $-22.42M ▲ | 0% | $-0.34 ▲ | $-22.05M ▲ |
| Q4-2024 | $0 | $26.72M ▲ | $-31.33M ▼ | 0% | $-0.48 ▼ | $-30.67M ▼ |
| Q3-2024 | $0 | $26.3M | $-24.02M | 0% | $-0.36 | $-23.6M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $30.66M ▲ | $39.96M ▼ | $39.05M ▼ | $911K ▼ |
| Q2-2025 | $28.13M ▼ | $42.33M ▼ | $40.73M ▲ | $1.59M ▼ |
| Q1-2025 | $37.09M ▼ | $45.74M ▼ | $19.31M ▼ | $26.42M ▼ |
| Q4-2024 | $60.03M ▼ | $67.7M ▼ | $20.68M ▲ | $47.02M ▼ |
| Q3-2024 | $80.19M | $89.94M | $17.38M | $72.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-8.38M ▲ | $-18.48M ▲ | $-4K ▲ | $21.27M ▲ | $2.53M ▲ | $-18.48M ▲ |
| Q2-2025 | $-26.22M ▼ | $-19.82M ▲ | $-26K ▲ | $11.49M ▲ | $-8.96M ▲ | $-19.85M ▲ |
| Q1-2025 | $-22.42M ▲ | $-23.07M ▼ | $-28K ▼ | $0 | $-22.95M ▼ | $-23.1M ▼ |
| Q4-2024 | $-31.33M ▼ | $-19.63M ▲ | $-11K ▼ | $0 | $-20.15M ▲ | $-19.64M ▲ |
| Q3-2024 | $-24.02M | $-20.81M | $-10K | $0 | $-20.56M | $-20.82M |
CEO
Mai-Britt Zocca
Compensation Summary
(Year 2024)
Salary $567,788
Option Awards $931,350
Incentive Plan Pay $283,894
All Other Compensation $56,779
Total Compensation $1,839,811
Industry Biotechnology
Sector Healthcare
Went public November 5, 2021
Method of going public IPO
Full time employees 80
Ratings Snapshot
Rating : C-
Discounted Cash Flow 4
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Most Recent Analyst Grades
Grade Summary
Overweight 2
Neutral 1
Hold 1
Showing Top 4 of 4
Price Target
Target High $3
Target Low $3
Target Median $3
Target Consensus $3
Institutional Ownership
NOVO HOLDINGS A/S
Shares:2.51M
Value:$1.35M
IKARIAN CAPITAL, LLC
Shares:1.53M
Value:$817.88K
MILLENNIUM MANAGEMENT LLC
Shares:1.39M
Value:$746.32K
Summary
% Of Shares Owned 13.75%
Total Number Of Holders 22
Showing Top 3 of 22